Nursing(Degree) · First Year · NUR101
Anatomy and Physiology
Anatomy and Physiology is one of the most important foundation courses for nursing students in Zambia. This course helps you understand how the human body is structured and how it functions, from major organs to body systems such as the nervous, cardiovascular, respiratory, and digestive …
Read more
Anatomy and Physiology is one of the most important foundation courses for nursing students in Zambia. This course helps you understand how the human body is structured and how it functions, from major organs to body systems such as the nervous, cardiovascular, respiratory, and digestive systems. A strong grasp of this subject is essential for exams set by nursing schools and regulatory bodies in Zambia. At 25schools, we simplify complex anatomy concepts using exam-focused questions, diagrams, and clear explanations designed for nursing exams. Whether you are preparing for tests, assignments, or final examinations, this course builds the clinical understanding every successful nurse needs. Start studying with 25schools today and gain the confidence to excel in anatomy and physiology exams.
-
Coming soon
Topic 190Coming soon
Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is the most common primary liver cancer, the third leading cause of cancer death worldwide, and a MAJOR ONCOLOGICAL PROBLEM IN ZAMBIA, driven by high prevalence of chronic hepatitis B (HBV), hepatitis C (HCV), and increasing non-alcoholic fatty liver disease (NAFLD)/alcoholic liver disease (ALD)-related cirrhosis. For Zambian students, HCC is a DEVASTATING, FREQUENTLY FATAL DISEASE, but EARLY DETECTION THROUGH SURVEILLANCE CAN BE CURATIVE. Pathophysiology: 90% arise in CIRRHOSIS. Chronic liver injury → hepatocyte regeneration, necrosis, fibrosis, genomic instability, telomere shortening → clonal expansion of malignant hepatocytes. HBV: direct integration into host genome (cis/trans activation of oncogenes), even in non-cirrhotic liver. HCV: cirrhosis-driven, oxidative stress. AFB1 (aflatoxin B1): TP53 mutation (R249S). Clinical: EARLY HCC: ASYMPTOMATIC—detected by surveillance ultrasound. ADVANCED HCC: RIGHT UPPER QUADRANT PAIN, WEIGHT LOSS, ANOREXIA, ABDOMINAL MASS, JAUNDICE, ascites (portal vein invasion, underlying cirrhosis), fever, paraneoplastic syndromes (hypercalcaemia, hypoglycaemia, polycythaemia, hypercholesterolaemia). DECOMPENSATION OF CIRRHOSIS without obvious precipitant. Diagnosis: RADIOLOGICAL—NON-INVASIVE DIAGNOSIS IN CIRRHOSIS. LIRADS (Liver Imaging Reporting and Data System). CT/MRI: ARTERIAL PHASE HYPERENHANCEMENT + WASHOUT (portal venous/delayed phases) + CAPSULE (late enhancement). LIRADS-5 = definite HCC. BIOPSY: indicated if atypical imaging (LIRADS-3/4), non-cirrhotic liver, suspected metastasis. LAB: AFP elevated (>200 ng/mL) in 60-70% (non-specific, normal in 30%). SCREENING: Cirrhotic patients (any aetiology), non-cirrhotic HBV (Asian males >40y, African males >20y, females >50y, family history HCC). SURVEILLANCE: ULTRASOUND ± AFP q6 MONTHS. Staging: BCLC (Barcelona Clinic Liver Cancer) STAGING SYSTEM—integrates tumour burden, liver function (Child-Pugh), performance status (ECOG). BCLC 0/A = early, potentially CURATIVE. BCLC B = intermediate, TACE. BCLC C = advanced, systemic therapy. BCLC D = terminal, palliative care. Management: MULTIDISCIPLINARY. BCLC 0/A: RESECTION (solitary tumour, non-cirrhotic, preserved liver function, no portal hypertension), LIVER TRANSPLANTATION (Milan criteria: single ≤5cm, ≤3 lesions ≤3cm, no extrahepatic spread, no vascular invasion), LOCAL ABLATION (RFA, MWA, PEI—tumours ≤3cm). BCLC B: TRANSARTERIAL CHEMOEMBOLIZATION (TACE), TARE (Y-90). BCLC C: SYSTEMIC THERAPY—TYROSINE KINASE INHIBITORS (sorafenib, lenvatinib—first-line), REGORAFENIB, CABOZANTINIB, RAMUCIRUMAB (AFP ≥400), IMMUNOTHERAPY (atezolizumab + bevacizumab—new standard, improved survival). BCLC D: BEST SUPPORTIVE CARE, pain control, symptom management. Prognosis: EARLY HCC (BCLC 0/A): 5-year survival 50-80%. ADVANCED HCC (BCLC C): median survival 6-12 months. Untreated: 3-6 months. Zambian context: HCC is a MAJOR KILLER. HBV is the LEADING CAUSE (80%). HCV, alcohol, NAFLD also contribute. Aflatoxin exposure (contaminated maize, groundnuts) is a co-factor. PRESENTATION: LATE (advanced BCLC C/D), young age (30-50 years), often non-cirrhotic HBV-related. DIAGNOSIS: ultrasound is accessible (portal vein invasion, mass), AFP is inexpensive. CT/MRI limited availability, cost. LIRADS reporting not routine. MANAGEMENT: RESECTION—available, but often not feasible (advanced disease, underlying cirrhosis, portal hypertension). TACE—available (Lusaka). SORAFENIB—available (National Cancer Hospital). ATEZOLIZUMAB/BEVACIZUMAB—unavailable. LENVATINIB, REGORAFENIB—unavailable. LIVER TRANSPLANT—unavailable. PALLIATIVE CARE—limited. PREVENTION IS KEY: UNIVERSAL HBV VACCINATION (infant, catch-up), ANTIVIRAL THERAPY for chronic HBV (tenofovir) and HCV (DAAs) to PREVENT CIRRHOSIS AND HCC. HCC SURVEILLANCE (ultrasound q6m) in high-risk patients (cirrhosis, non-cirrhotic HBV) is FEASIBLE and COST-EFFECTIVE. EARLY DETECTION SAVES LIVES. Patient education: HCC is PREVENTABLE (vaccination, antivirals, aflatoxin avoidance, alcohol moderation).
-
Coming soon
Topic 191Coming soon
Hepatorenal Syndrome
Hepatorenal syndrome (HRS) is a form of functional renal failure occurring in patients with advanced cirrhosis and ascites, characterized by severe renal vasoconstriction in the setting of systemic vasodilation and normal renal histology. For Zambian students, HRS is a COMMON, OFTEN FATAL complication of decompensated cirrhosis, but EARLY RECOGNITION AND PHARMACOLOGICAL THERAPY CAN IMPROVE SURVIVAL AND BRIDGE TO LIVER TRANSPLANTATION. Pathophysiology: PORTAL HYPERTENSION → SPLANCHNIC VASODILATION → effective arterial hypovolaemia → BARORECEPTOR-MEDIATED ACTIVATION of renin-angiotensin-aldosterone system (RAAS), sympathetic nervous system (SNS), and antidiuretic hormone (ADH) → renal VASOCONSTRICTION, sodium and water retention, ascites, hyponatraemia. In advanced cirrhosis, this compensatory vasoconstriction becomes maladaptive, leading to progressive renal failure. HRS is a DIAGNOSIS OF EXCLUSION, requiring absence of hypovolaemia, shock, nephrotoxic drugs, and intrinsic renal disease. Clinical classification: HRS-AKI (formerly Type 1)—acute, rapid progressive renal failure: doubling of serum creatinine to >2.5 mg/dL (221 μmol/L) in <2 weeks. Often precipitated by spontaneous bacterial peritonitis (SBP), gastrointestinal haemorrhage, large-volume paracentesis without albumin. HIGH MORTALITY (>50% at 1 month). HRS-NAKI (formerly Type 2)—moderate, stable or slowly progressive renal impairment (creatinine 1.5-2.5 mg/dL), associated with REFRACTORY ASCITES. Better prognosis than HRS-AKI, but poor long-term survival. Diagnosis: INTERNATIONAL CLUB OF ASCITES (ICA) CRITERIA (2019): 1) Cirrhosis with ascites, 2) Diagnosis of AKI (increase in creatinine ≥0.3 mg/dL within 48h OR ≥50% from baseline within 7 days), 3) No response after 48h of volume expansion with albumin (1g/kg/day, max 100g), 4) Absence of shock, 5) No current or recent nephrotoxic drugs (NSAIDs, aminoglycosides, contrast), 6) No macroscopic signs of structural kidney injury (normal renal ultrasound, normal urine sediment, fractional excretion of sodium <1%). URINALYSIS: bland sediment, minimal proteinuria. URINE SODIUM: low (<10 mEq/L) due to intense renal vasoconstriction. Management: HRS-AKI (MEDICAL EMERGENCY). FIRST-LINE: VASOCONSTRICTORS + ALBUMIN. TERRPRESSIN (IV bolus 0.5-1 mg q4-6h, titrate to response) + ALBUMIN (20-40g/day) is MOST EFFECTIVE. NORADRENALINE (0.5-3 mg/h IV continuous infusion) is ALTERNATIVE if terlipressin unavailable. MIDODRINE + OCTREOTIDE + ALBUMIN (less effective, used if terlipressin/noradrenaline unavailable). GOAL: reduction in creatinine to <1.5 mg/dL or ≥50% decrease from baseline. TREAT PRECIPITANT: SBP (antibiotics + albumin 1.5g/kg day 1, 1g/kg day 3), GI bleed (antibiotics, volume resuscitation), large-volume paracentesis (albumin 6-8g/L removed). AVOID: NSAIDs, aminoglycosides, IV contrast. LIVER TRANSPLANTATION: DEFINITIVE THERAPY for HRS. Survival post-transplant is excellent. HRS-NAKI: management of refractory ascites (large-volume paracentesis + albumin, TIPS). Liver transplant evaluation. Prognosis: HRS-AKI: Without treatment, median survival <2 weeks. With terlipressin/albumin, response rate 40-60%, improved transplant-free survival. HRS-NAKI: median survival 6 months without transplant. Zambian context: HRS IS COMMON, UNDERDIAGNOSED, AND OFTEN FATAL. High burden of cirrhosis (HBV, alcohol, NAFLD). DIAGNOSTIC CHALLENGES: serum creatinine may be falsely low in cirrhosis (muscle wasting, malnutrition), delayed recognition. ICA criteria require baseline creatinine—often unknown. URINALYSIS, RENAL ULTRASOUND (exclude obstruction) essential. ALBUMIN is expensive, limited availability. TERLIPRESSIN is expensive, not on essential medicines list; NORADRENALINE (ICU setting) more accessible. MIDODRINE + OCTREOTIDE may be available. LIVER TRANSPLANT UNAVAILABLE. PREVENTION: PRIMARY PROPHYLAXIS: albumin for SBP (1.5g/kg day 1, 1g/kg day 3), for large-volume paracentesis (6-8g/L), for HRS prevention in SBP. SECONDARY PROPHYLAXIS: long-term norfloxacin (or ciprofloxacin) in patients with prior SBP and low protein ascites (<1.5g/dL) reduces SBP recurrence and HRS. Management of HRS in Zambia requires: 1) EARLY RECOGNITION (monitor creatinine in all cirrhotics with acute decompensation), 2) AGGRESSIVE TREATMENT OF PRECIPITANTS (SBP, GI bleed), 3) VOLUME EXPANSION (albumin if available, else crystalloids with caution), 4) VASOCONSTRICTORS (noradrenaline, midodrine/octreotide), 5) PALLIATIVE CARE for non-responders (dialysis not indicated without transplant candidacy). This is a HIGH-YIELD, HIGH-MORTALITY topic. MASTER IT.
-
Coming soon
Topic 192Coming soon
Spontaneous Bacterial Peritonitis
Spontaneous bacterial peritonitis (SBP) is an infection of ascitic fluid in patients with cirrhosis and portal hypertension, in the absence of an intra-abdominal surgically treatable source. It is the MOST COMMON INFECTION in cirrhotic patients, with high mortality (20-40%), and is a MEDICAL EMERGENCY requiring IMMEDIATE DIAGNOSIS AND ANTIBIOTIC THERAPY. For Zambian students, SBP is a FREQUENT AND OFTEN FATAL COMPLICATION of decompensated cirrhosis (HBV, alcohol, NAFLD). MASTERY OF SBP DIAGNOSIS AND MANAGEMENT IS LIFE-SAVING. Pathophysiology: BACTERIAL TRANSLOCATION—migration of enteric organisms (E. coli, Klebsiella, Streptococcus, Enterococcus) from the intestinal lumen to mesenteric lymph nodes, then to systemic circulation, and seeding of ascitic fluid. Cirrhosis-associated immune dysfunction (impaired neutrophil, macrophage, complement function, low ascitic fluid protein) predisposes to bacterial proliferation in ascites. Risk factors: LOW ASCITIC FLUID PROTEIN (<1.5 g/dL), prior SBP, variceal haemorrhage (high-risk, prophylactic antibiotics), advanced liver disease (high Child-Pugh/MELD). Clinical: SYMPTOMS (only 50-60%): FEVER (50-80%), ABDOMINAL PAIN (50-70%), ALTERED MENTAL STATUS (HEPATIC ENCEPHALOPATHY, 30-50%), diarrhoea, ileus, hypothermia, shock. ASYMPTOMATIC (10-30%)—incidental finding on diagnostic paracentesis. HIGH INDEX OF SUSPICION in ANY cirrhotic with ascites and deterioration (renal impairment, encephalopathy, hypotension, GI bleed, jaundice). Diagnosis: DIAGNOSTIC PARACENTESIS—MANDATORY for ALL cirrhotic patients with ascites at admission, and with ANY sign/symptom of SBP or clinical deterioration. Contraindications: none absolute; coagulopathy is NOT a contraindication (benefit >> risk). Bedside ultrasound guidance preferred. ASCITIC FLUID NEUTROPHIL (PMN) COUNT >250 cells/μL is DIAGNOSTIC of SBP. ASCITIC FLUID CULTURE: inoculate at bedside into blood culture bottles (aerobic, anaerobic) increases yield to 80%. GRAM STAIN: positive in only 30%. OTHER TESTS: ascitic fluid protein (<1.5 g/dL = high risk), glucose (<50 mg/dL), LDH (>225 IU/L), pH (<7.35), lactate. Distinguish from SECONDARY PERITONITIS (surgical emergency): suspected if: polymicrobial infection, very high PMN count (>10,000), elevated ascitic fluid LDH, glucose <50 mg/dL, total protein >1g/dL, failure to respond to antibiotics within 48h. Requires CT imaging, surgical consultation. Management: IMMEDIATE EMPIRIC ANTIBIOTIC THERAPY—DO NOT WAIT FOR CULTURE RESULTS. THIRD-GENERATION CEPHALOSPORIN (cefotaxime 2g IV q8h, or ceftriaxone 2g IV q24h) is FIRST-LINE, covers 90% of organisms. ALTERNATIVES: piperacillin-tazobactam, ampicillin-sulbactam, carbapenem (if high risk MDR, nosocomial). DURATION: 5-7 days (5 days sufficient if clinical improvement). RESPONSE ASSESSMENT: repeat diagnostic paracentesis at 48h. If PMN count decreases by <25%, suspect resistance, secondary peritonitis, or fungal infection—adjust antibiotics. INTRAVENOUS ALBUMIN: 1.5 g/kg at diagnosis, 1 g/kg on day 3. REDUCES MORTALITY (from 30% to 10%) by preventing HEPATORENAL SYNDROME (HRS). Indicated if: serum creatinine >1 mg/dL, BUN >30 mg/dL, or total bilirubin >4 mg/dL. PROPHYLAXIS: PRIMARY PROPHYLAXIS: norfloxacin 400mg/day (or ciprofloxacin 500mg/day, TMP-SMX DS daily) in cirrhotics with ascitic fluid protein <1.5 g/dL AND advanced liver disease (Child-Pugh ≥9, MELD ≥15) or renal impairment (creatinine ≥1.2 mg/dL, BUN ≥25, hyponatraemia ≤130). REDUCES SBP, HRS, and improves survival. SECONDARY PROPHYLAXIS: norfloxacin 400mg/day (or ciprofloxacin 500mg/day, TMP-SMX DS daily) LIFELONG after SBP episode (or until liver transplant). REDUCES SBP recurrence from 70% to 20%. Prognosis: SBP is a MARKER OF POOR PROGNOSIS. In-hospital mortality 20-40%. 1-year survival after SBP 30-50%. All SBP survivors should be REFERRED FOR LIVER TRANSPLANT EVALUATION. Zambian context: SBP IS COMMON. High prevalence of cirrhosis (HBV, alcohol). Diagnostic paracentesis is UNDERUTILIZED—FEAR OF COAGULOPATHY (unfounded). EQUIP: ultrasound, ascitic tap needle, blood culture bottles. CEFTRIAXONE is available, inexpensive. ALBUMIN is expensive, limited availability—PRIORITIZE for high-risk patients (creatinine ↑, bilirubin ↑). NORFLOXACIN may be unavailable; CIPROFLOXACIN, TMP-SMX are alternatives. LIVER TRANSPLANT UNAVAILABLE. PREVENTION (primary and secondary prophylaxis) IS KEY—FEASIBLE, COST-EFFECTIVE, LIFE-SAVING. Patient education: signs of SBP (fever, abdominal pain, confusion), need for urgent medical attention. This is a HIGH-YIELD topic. MASTER SBP: DIAGNOSE, TREAT, PREVENT.
-
Coming soon
Topic 193Coming soon
Portal Hypertension and Variceal Hemorrhage
Portal hypertension is the hemodynamic abnormality complicating cirrhosis, defined as a hepatic venous pressure gradient (HVPG) >5 mmHg (clinically significant >10 mmHg). It is responsible for the most lethal complications of cirrhosis: VARICEAL HEMORRHAGE, ASCITES, and HEPATIC ENCEPHALOPATHY. For Zambian students, VARICEAL HEMORRHAGE is a MEDICAL EMERGENCY with HIGH MORTALITY (15-20% at 6 weeks). A SYSTEMATIC, PROTOCOL-DRIVEN APPROACH SAVES LIVES. Pathophysiology: CIRRHOSIS → increased intrahepatic resistance (fibrosis, regenerative nodules, sinusoidal remodelling, endothelial dysfunction, vasoconstriction) → PORTAL HYPERTENSION. Splanchnic vasodilation (nitric oxide) increases portal inflow, exacerbating portal hypertension. PORTOSYSTEMIC COLLATERALS develop: ESOPHAGEAL VARICES (most common, most bleed), GASTRIC VARICES (less common, more severe bleeding), others (rectal, umbilical, retroperitoneal). Variceal hemorrhage occurs when variceal wall tension exceeds elastic limit (LaPlace's law: tension = transmural pressure × radius / wall thickness). Risk factors for first hemorrhage: large varices, red wale marks (high-risk stigmata), advanced cirrhosis (Child-Pugh B/C), ongoing alcohol use. Clinical: ACUTE UPPER GI BLEED: hematemesis (fresh blood, clots), melaena, haematochezia (massive bleed), haemodynamic instability (tachycardia, hypotension, shock), signs of cirrhosis (ascites, jaundice, spider naevi, encephalopathy). Diagnosis: CLINICAL—presumed variceal bleed until proven otherwise. UPPER ENDOSCOPY (within 12-24h) confirms diagnosis, identifies source, and provides therapy. Management: RESUSCITATION, ENDOSCOPY, PHARMACOLOGICAL, and SECONDARY PROPHYLAXIS. PHASE 1: RESUSCITATION (IMMEDIATE). AIRWAY: protect in altered mental status (encephalopathy, haematemesis). BREATHING: supplemental oxygen. CIRCULATION: IV ACCESS (two large-bore 16-18G). FLUID RESUSCITATION: RESTRICTIVE strategy—target systolic 90-100 mmHg, MAP ≥65 mmHg, haemoglobin ≥7 g/dL (≥8 g/dL in massive bleed, cardiac disease). AVOID EXCESSIVE FLUID—increases portal pressure, rebleeding risk. BLOOD TRANSFUSION: threshold Hb <7 g/dL. CORRECT COAGULOPATHY: vitamin K, fresh frozen plasma (if active bleeding, invasive procedure), platelets if <50,000. ANTIBIOTICS: IV ceftriaxone 1g/day (or norfloxacin 400mg bd) for 7 days—REDUCES REBLEEDING, INFECTION, MORTALITY. PHASE 2: PHARMACOLOGICAL (IMMEDIATE, CONTINUE 3-5 days). VASOACTIVE DRUGS: TERLIPRESSIN (IV 2mg q4h → 1mg q4h after bleeding controlled), OCTREOTIDE (IV bolus 50mcg, infusion 50mcg/h), or SOMATOSTATIN (IV bolus 250mcg, infusion 250mcg/h). Reduce portal pressure, control acute bleeding, facilitate endoscopy. PHASE 3: ENDOSCOPIC THERAPY (within 12-24h). ESOPHAGEAL VARICES: ENDOSCOPIC VARICEAL LIGATION (EVL, band ligation)—preferred, more effective, safer than sclerotherapy. GASTRIC VARICES: CYANOACRYLATE (glue) INJECTION. Endoscopy also excludes non-variceal causes (ulcer, Mallory-Weiss, erosive disease). PHASE 4: BALLOON TAMPONADE (Sengstaken-Blakemore, Minnesota tube)—TEMPORIZING MEASURE (max 24h) for UNCONTROLLED BLEEDING (failure of pharmacologic + endoscopic therapy), bridge to definitive therapy (TIPS). High risk of aspiration, oesophageal perforation, necrosis. PHASE 5: TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS). INDICATIONS: SALVAGE THERAPY for refractory acute variceal haemorrhage, PREVENTION OF REBLEEDING in high-risk patients (Child-Pugh B/C, HVPG >20). REDUCES portal pressure, controls bleeding, but increases encephalopathy risk. SECONDARY PROPHYLAXIS (PREVENTION OF REBLEEDING, LIFELONG). COMBINATION: NON-SELECTIVE BETA-BLOCKER (NSBB: propranolol, nadolol, carvedilol) + ENDOSCOPIC VARICEAL LIGATION (EVL) every 2-4 weeks until varices obliterated. NSBB reduces portal pressure (target heart rate 50-60 bpm, but dose titrated to tolerance, not HR). Carvedilol (6.25-12.5mg/day) more effective than propranolol/nadolol. TIPS: for failures of NSBB/EVL, refractory/recurrent bleeding. PRIMARY PROPHYLAXIS (PREVENTION OF FIRST BLEED). INDICATIONS: MEDIUM/LARGE VARICES (>5mm) OR SMALL VARICES WITH HIGH-RISK STIGMATA (red wale marks) OR CHILD-PUGH B/C. NSBB (propranolol, carvedilol) OR EVL. Choice: EVL preferred for high-risk varices (large, red signs), NSBB for lower risk, patient preference, resource. Carvedilol more effective than propranolol. Prognosis: Acute variceal haemorrhage: 6-week mortality 15-20% (higher with advanced cirrhosis, HCC, rebleeding, infection). Rebleeding rate without prophylaxis: 60-80% within 1 year. With NSBB+EVL: rebleeding 15-25%. Zambian context: PORTAL HYPERTENSION AND VARICEAL HEMORRHAGE ARE COMMON (HBV, alcohol cirrhosis). ACUTE MANAGEMENT CHALLENGES: ENDOSCOPY (available tertiary centres, but not 24/7, delays), TERLIPRESSIN (expensive, not EML, limited availability), OCTREOTIDE (available), PROPRANOLOL (available, inexpensive), CARVEDILOL (available), EVL (available tertiary centres), TIPS (NOT AVAILABLE). BALLOON TAMPONADE—skill fading. Antibiotics (ceftriaxone) available. BLOOD TRANSFUSION—restrictive strategy (cost, availability). SECONDARY PROPHYLAXIS: PROPRANOLOL + EVL (feasible, life-saving). PRIMARY PROPHYLAXIS: SCREENING ENDOSCOPY for all cirrhotics—not feasible (volume, cost). Pragmatic approach: START NSBB (propranolol, carvedilol) EMPIRICALLY in cirrhotics with CLINICALLY SIGNIFICANT PORTAL HYPERTENSION (ascites, platelets <150,000, splenomegaly) and no contraindications (asthma, heart block, refractory ascites—caution). Patient education: ADHERENCE to NSBB, alcohol abstinence, signs of bleeding. This is a HIGH-YIELD, LIFE-SAVING topic. MASTER PORTAL HYPERTENSION AND VARICEAL HEMORRHAGE.
-
Coming soon
Topic 194Coming soon
Hepatic Encephalopathy
Hepatic encephalopathy (HE) is a neuropsychiatric syndrome complicating acute or chronic liver failure, characterized by a wide spectrum of cognitive, psychiatric, and motor disturbances, ranging from subtle subclinical deficits to deep coma. For Zambian students, HE is an EXTREMELY COMMON, FREQUENTLY RECURRENT, AND OFTEN STIGMATIZED complication of cirrhosis. EARLY RECOGNITION AND PROMPT TREATMENT IMPROVE QUALITY OF LIFE AND REDUCE HOSPITALIZATION AND MORTALITY. Pathophysiology: MULTIFACTORIAL. The dominant hypothesis: impaired hepatic clearance of GUT-DERIVED NEUROTOXINS (AMMONIA, manganese, benzodiazepine-like substances, mercaptans, short-chain fatty acids) due to portosystemic shunting and hepatocellular failure → systemic accumulation → crossing blood-brain barrier → ASTROCYTE SWELLING (Alzheimer type II astrocytes), oxidative stress, neuroinflammation, impaired neurotransmission (glutamate, GABA). AMMONIA is central, but not sole mediator. PRECIPITANTS: IDENTIFY AND TREAT URGENTLY (mnemonic: VIOLATED). V: Vascular (variceal bleed), I: Infection (SBP, pneumonia, UTI), O: Over-diuresis (dehydration, prerenal azotaemia, hypokalaemia), L: Laxatives (excessive diarrhoea), A: Acid-base/electrolyte (hyponatraemia, hypokalaemia, alkalosis), T: Toxins (alcohol, sedatives, opioids), E: Everything else (constipation, high-protein meal, TIPS, hepatocellular carcinoma, progressive liver failure). D: Drugs (benzodiazepines, narcotics, antipsychotics). Clinical: SPECTRUM—West Haven Criteria (0-IV). GRADE 0: minimal HE—normal mental status, subtle deficits on psychometric testing. GRADE 1: trivial—euphoria/anxiety, shortened attention span, impaired addition/subtraction, altered sleep rhythm. GRADE 2: lethargy, apathy, disorientation (time), personality change, inappropriate behaviour, asterixis (positive). GRADE 3: somnolent but arousable, confusion (place), disorientation, gross disorientation, asterixis (may be absent). GRADE 4: coma—unarousable. MOTOR SIGNS: asterixis (flapping tremor, bilateral, not specific to HE), hyperreflexia, clonus, rigidity, decorticate/decerebrate posturing (grade 4). OTHER: fetor hepaticus (musty, sweet breath—dimethylsulphide, not specific), constructional apraxia. Diagnosis: CLINICAL—presence of characteristic neuropsychiatric abnormalities in patient with liver disease/portosystemic shunting, after EXCLUSION OF OTHER CAUSES of altered mental status. ESSENTIAL: EXCLUDE alternative diagnoses: intracranial haemorrhage (subdural, trauma), stroke, meningitis/encephalitis, sepsis (CNS), hypoglycaemia, Wernicke's, intoxication (alcohol, benzodiazepines, opioids), electrolyte disturbances (hyponatraemia, hyper/hypocalcaemia), post-ictal state. LABORATORY: ammonia levels—elevated (arterial > venous), but correlation with severity is POOR, NOT diagnostic, NOT prognostic. USE with caution. EEG: generalized slowing (triphasic waves), non-specific. PSYCHOMETRIC TESTS: PHES (portosystemic encephalopathy score), animal naming test (number of animals in 1 minute, <10 abnormal, bedside). MANAGEMENT: A THREE-PRONGED APPROACH. 1) IDENTIFY AND TREAT PRECIPITANT(S)—MOST IMPORTANT STEP. 2) REDUCE AMMONIA PRODUCTION/ABSORPTION. LACTULOSE: first-line therapy. ORAL/NG: 30-45 mL q1h until bowel movement, then titrate to 2-3 soft stools/day. RETENTION ENEMA: 300 mL + 700 mL water, if cannot take orally. RECTAL: 300 mL + 700 mL water q4-6h. Mechanism: acidifies colon, converts NH3 to NH4+ (non-absorbable), cathartic, prebiotic (promotes non-urease-producing bacteria). RIFAXIMIN 550mg BD: second-line, adjunct to lactulose (reduces recurrence). Antibiotic, reduces gut urease-producing bacteria. Not absorbed, better tolerated than neomycin/metronidazole. 3) SUPPORTIVE CARE. AIRWAY PROTECTION: grade 3/4 HE, risk of aspiration. NUTRITION: DO NOT RESTRICT PROTEIN. Provide 1.2-1.5 g/kg/day protein (maintain nitrogen balance, sarcopenia). BRANCHED-CHAIN AMINO ACIDS (BCAA): controversial, no mortality benefit, may improve HE. ZINC: supplementation if deficient (cofactor for urea cycle enzymes). AVOID: benzodiazepines, opioids, sedatives. Lactulose is also TREATMENT, not just prevention. REFRACTORY HE: TIPS reduction/occlusion (if TIPS-related), liver transplant evaluation. Prognosis: HE is a MARKER OF POOR PROGNOSIS. First episode of overt HE: 1-year survival 30-50%. Recurrent HE: impaired quality of life, high caregiver burden, increased hospitalization, mortality. Liver transplant is definitive. Zambian context: HE IS EXTREMELY COMMON. High prevalence of cirrhosis (HBV, alcohol). Precipitants: infection (SBP, TB, malaria, HIV), GI bleed, constipation, non-adherence to lactulose, sedatives (benzodiazepines widely used), electrolyte disturbance. DIAGNOSIS IS CLINICAL. Ammonia testing—limited availability, not essential. LACTULOSE IS AVAILABLE, INEXPENSIVE, LIFE-SAVING. RIFAXIMIN is expensive, not on EML, generally unavailable. PROTEIN RESTRICTION IS HARMFUL—DO NOT DO IT. Patient/caregiver education: HE is a COMPLICATION OF LIVER DISEASE, not a psychiatric illness; reduce stigma. LACTULOSE ADHERENCE: titrate to 2-3 soft stools/day—if diarrhoea, reduce dose; if constipated, increase dose. Recognize early signs (reversal sleep-wake, irritability, forgetfulness, asterixis). EARLY TREATMENT PREVENTS HOSPITALIZATION. MASTER HE: RECOGNIZE, IDENTIFY PRECIPITANT, LACTULOSE, NO PROTEIN RESTRICTION, PATIENT EDUCATION.
-
Coming soon
Topic 195Coming soon
Ascites
Ascites is the pathological accumulation of fluid in the peritoneal cavity, the MOST COMMON complication of cirrhosis, marking the transition from compensated to decompensated disease. For Zambian students, ascites is a DAILY CLINICAL PROBLEM, with high prevalence of cirrhosis (HBV, alcohol, NAFLD). MASTERY OF ASCITES DIAGNOSIS, MANAGEMENT, AND COMPLICATIONS (SBP, HRS, refractory ascites) IS ESSENTIAL. Pathophysiology: PORTAL HYPERTENSION (HVPG >10 mmHg) + SODIUM AND WATER RETENTION (RAAS, SNS, ADH activation) → increased hydrostatic pressure, increased plasma volume, decreased oncotic pressure (hypoalbuminaemia) → NET FILTRATION > LYMPHATIC DRAINAGE → ascites. Diagnosis: CLINICAL—bulging flanks, shifting dullness (≥1500mL), fluid wave (≥3000mL). IMAGING: ultrasound—confirms, quantifies, guides paracentesis, excludes hepatic vein thrombosis (Budd-Chiari). DIAGNOSTIC PARACENTESIS: INDICATIONS: ALL patients with ascites at presentation, and for ANY clinical deterioration (fever, abdominal pain, encephalopathy, renal impairment, GI bleed). MANDATORY. Contraindications: none absolute. Bedside ultrasound guidance preferred. SEND ASCITIC FLUID FOR: CELL COUNT WITH DIFFERENTIAL (essential), CULTURE (inoculate blood culture bottles bedside, aerobic + anaerobic), TOTAL PROTEIN, ALBUMIN (to calculate serum-ascites albumin gradient, SAAG), GRAM STAIN, GLUCOSE, LDH, AMYLASE, AFB (if suspected TB), CYTOLOGY (if suspected malignancy). SAAG = serum albumin - ascitic fluid albumin (same day). HIGH SAAG (≥1.1 g/dL) indicates PORTAL HYPERTENSION (cirrhosis, 97% accuracy). LOW SAAG (<1.1 g/dL) indicates non-portal hypertension causes (peritoneal carcinomatosis, TB, pancreatic, nephrotic, serositis). ASCITIC FLUID PROTEIN: low (<1.5 g/dL) = high risk SBP (cirrhosis, cardiac ascites). high (>2.5 g/dL) = cardiac ascites, malignant, TB, pancreatic. Management: SODIUM RESTRICTION (88 mmol/day = 2g sodium/day). FLUID RESTRICTION: NOT indicated unless hyponatraemia <120-125 mEq/L or symptomatic. DIURETICS: FIRST-LINE COMBINATION: SPIRONOLACTONE (aldosterone antagonist) + FUROSEMIDE. Starting: spironolactone 100mg + furosemide 40mg, once daily. Titration: increase every 3-5 days (spironolactone 100mg, furosemide 40mg increments). MAX: spironolactone 400mg/day, furosemide 160mg/day. MAINTENANCE: lowest effective dose. MONITOR: weight, urine output, electrolytes, creatinine. GOAL: weight loss 0.5-1 kg/day (with peripheral oedema), 0.5 kg/day (without oedema). AVOID: too rapid diuresis (renal impairment, electrolyte disturbance, pre-renal azotaemia). COMPLICATIONS: hyperkalaemia (spironolactone), gynaecomastia (spironolactone, painful, may switch to eplerenone or amiloride), hyponatraemia, renal impairment. REFRACTORY ASCITES: ascites that cannot be mobilized or recurs early after therapeutic paracentesis, despite optimal sodium restriction and high-dose diuretics (spironolactone 400mg, furosemide 160mg) or diuretic-intolerant. MANAGEMENT: SERIAL THERAPEUTIC PARACENTESIS + INTRAVENOUS ALBUMIN (6-8g/L ascites removed, if >5L removed). TRANSUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS): effective, reduces ascites, but increases encephalopathy risk, requires expertise. LIVER TRANSPLANT: definitive therapy. HEPATORENAL SYNDROME (HRS), SPONTANEOUS BACTERIAL PERITONITIS (SBP): see dedicated topics. Prognosis: Development of ascites is a POOR PROGNOSTIC MARKER. 1-year mortality 20-30%, 5-year mortality 50-80%. REFRACTORY ASCITES: median survival 6 months. Liver transplant evaluation is ESSENTIAL for all patients with ascites. Zambian context: ASCITES IS COMMON. CAUSES: cirrhosis (HBV, alcohol), tuberculous peritonitis (TB, high prevalence), cardiac (right heart failure, constrictive pericarditis, pulmonary hypertension), malignant (peritoneal carcinomatosis—ovarian, gastric, pancreatic, lymphoma), nephrotic syndrome, pancreatic. DIAGNOSTIC PARACENTESIS IS UNDERUTILIZED—FEAR OF COAGULOPATHY (unfounded). Ultrasound guidance (available). LABORATORY: cell count, albumin, total protein, culture, AFB. SAAG calculation requires serum and ascitic albumin (accessible). TB PERITONITIS: SAAG <1.1, high protein >2.5g/dL, lymphocytosis, AFB smear negative (low yield), culture (long delay), Xpert MTB/RIF (on ascitic fluid, low sensitivity), adenosine deaminase (ADA) >30-40 IU/L (good sensitivity/specificity, not widely available), peritoneal biopsy (laparoscopy, highest yield). MANAGEMENT: SODIUM RESTRICTION (challenging—dietary education). SPIRONOLACTONE + FUROSEMIDE (available, inexpensive). THERAPEUTIC PARACENTESIS (available, skill). ALBUMIN (expensive, limited). TIPS (NOT AVAILABLE). LIVER TRANSPLANT (NOT AVAILABLE). PREVENTION: treat underlying cirrhosis (HBV: tenofovir, alcohol abstinence). Patient education: sodium restriction (do NOT add salt at table, avoid processed foods), daily weight, medication adherence, recognize signs of SBP (fever, abdominal pain, confusion), need for urgent paracentesis. MASTER ASCITES: DIAGNOSTIC PARACENTESIS, SAAG, DIURETICS, REFRACTORY ASCITES, COMPLICATIONS.
-
Coming soon
Topic 196Coming soon
Acute Liver Failure
Acute liver failure (ALF) is a RARE but CATASTROPHIC syndrome characterized by rapid development of hepatocellular dysfunction, coagulopathy (INR ≥1.5), and hepatic encephalopathy in a patient WITHOUT pre-existing cirrhosis or chronic liver disease (onset <26 weeks). For Zambian students, ALF is a MEDICAL EMERGENCY requiring URGENT RECOGNITION, TRANSFER TO TERTIARY CENTRE, and MULTIDISCIPLINARY INTENSIVE CARE. MORTALITY IS HIGH (30-50%), but ETIOLOGY-SPECIFIC THERAPY AND LIVER TRANSPLANTATION CAN BE LIFE-SAVING. Etiology: VIRAL (Hepatitis A, B, E—endemic in Zambia, high mortality in pregnancy—HEV, HBV reactivation), DRUG-INDUCED (ACETAMINOPHEN—most common cause in UK/US, underrecognized in Zambia, traditional herbal remedies—significant cause, anti-tuberculous therapy—isoniazid, rifampicin, pyrazinamide), WILSON'S DISEASE, AUTOIMMUNE HEPATITIS, ISCHEMIC HEPATITIS (shock, sepsis), ACUTE FATTY LIVER OF PREGNANCY/HELLP, BUDD-CHIARI SYNDROME, INDETERMINATE (15-20%). Pathophysiology: MASSIVE HEPATOCYTE NECROSIS/APOPTOSIS → loss of synthetic function (coagulation factors, albumin), detoxification (ammonia, toxins), metabolic homeostasis (glucose, lactate). SYSTEMIC INFLAMMATORY RESPONSE SYNDROME (SIRS), MULTI-ORGAN FAILURE (MOF). Clinical: JAUNDICE (variable), HEPATIC ENCEPHALOPATHY (hallmark, cardinal feature, distinguishes ALF from acute hepatitis), COAGULOPATHY (INR ≥1.5), rapidly progressive. CEREBRAL EDEMA (intracranial hypertension)—leading cause of death, grade 3/4 encephalopathy. HYPOGLYCAEMIA (impaired gluconeogenesis, glycogen depletion), LACTIC ACIDOSIS, ACUTE KIDNEY INJURY (hepatorenal, acute tubular necrosis), INFECTION (SIRS, immune paresis), PANCREATITIS, HAEMODYNAMIC INSTABILITY (vasodilatory shock). Diagnosis: HISTORY: detailed medication (acetaminophen, ATT, herbs), risk factors for viral hepatitis, pregnancy, family history (Wilson's). LABORATORY: LFTs (AST/ALT markedly elevated—often >1000-2000 IU/L, except Wilson's, ischemic), BILIRUBIN (elevated), INR/PROLONGED PT (coagulopathy), AMMONIA (arterial, elevated, predictor of intracranial hypertension), GLUCOSE (low), CREATININE (AKI), ARTERIAL BLOOD GAS (lactate, pH). VIRAL SEROLOGY: HAV IgM, HBsAg, IgM anti-HBc, anti-HEV IgM, HCV Ab. AUTOANTIBODIES: ANA, SMA, anti-LKM1 (AIH). CERULOPLASMIN, COPPER STUDIES (Wilson's). ACETAMINOPHEN LEVEL. PREGNANCY TEST. IMAGING: abdominal ultrasound (exclude Budd-Chiari, cirrhosis, metastases, fatty liver). LIVER BIOPSY: transjugular (coagulopathy), may confirm etiology (AIH, Wilson's, malignancy, herpes), prognostic value. Management: THREE PRINCIPLES: 1) INTENSIVE CARE, 2) ETIOLOGY-SPECIFIC THERAPY, 3) LIVER TRANSPLANT EVALUATION. TRANSFER TO TERTIARY CENTRE WITH INTENSIVE CARE AND TRANSPLANT CAPABILITY (in Zambia, not available; transfer to high-income country? Not feasible; goal is OPTIMAL SUPPORTIVE CARE). INTENSIVE CARE: AIRWAY: intubation for grade 3/4 encephalopathy. BREATHING: mechanical ventilation (target normocapnia). CIRCULATION: fluid resuscitation, vasopressors (noradrenaline) for shock. TARGET: MAP ≥65 mmHg, cerebral perfusion pressure 50-80 mmHg. NEUROPROTECTION: HEAD OF BED ELEVATED 30°, AVOID STIMULATION, MANAGE INTRACRANIAL HYPERTENSION (mannitol, hypertonic saline, therapeutic hypothermia?, barbiturates?—limited evidence, NOT routine). SEIZURE PROPHYLAXIS: phenytoin? NOT routine. METABOLIC: GLUCOSE (IV dextrose, maintain >4 mmol/L), CORRECT COAGULOPATHY (vitamin K, fresh frozen plasma ONLY if invasive procedure or active bleeding), NUTRITION (enteral feeding). RENAL: continuous renal replacement therapy (CRRT) for AKI, acidosis, fluid overload, ammonia clearance. INFECTION: surveillance cultures, low threshold for antibiotics (high risk SIRS/sepsis). ETIOLOGY-SPECIFIC THERAPY: ACETAMINOPHEN: N-ACETYLCYSTEINE (NAC) IV—MOST EFFECTIVE if given early (<8-10h), but benefit up to 24-36h, improves transplant-free survival in non-acetaminophen ALF (all etiologies). VIRAL: HAV/HBV/HEV—supportive; HBV: entecavir/tenofovir (reduce replication, prevent reactivation). AIH: corticosteroids (prednisolone 40-60mg/day). WILSON'S DISEASE: D-penicillamine, zinc, plasmapheresis, CRRT. ACUTE FATTY LIVER OF PREGNANCY/HELLP: DELIVERY. HERBAL/DILI: stop offending agent. BUDD-CHIARI: anticoagulation, TIPS, transplant. INDETERMINATE: NAC, supportive. LIVER TRANSPLANTATION: DEFINITIVE THERAPY. INDICATIONS: KING'S COLLEGE CRITERIA, CLICHÉ CRITERIA. ACETAMINOPHEN: pH <7.3 (after resuscitation) OR INR >6.5 + creatinine >300 μmol/L + grade 3/4 encephalopathy. NON-ACETAMINOPHEN: INR >6.5 OR any 3 of: INR >3.5, age <10 or >40, bilirubin >300 μmol/L, jaundice to encephalopathy >7 days, unfavorable etiology (indeterminate, Wilson's, drug). Prognosis: WITHOUT TRANSPLANT: survival 30-50%. WITH TRANSPLANT: 1-year survival 80-90%. Causes of death: cerebral edema, MOF, sepsis. Zambian context: ALF IS UNDERDIAGNOSED, UNDER-RECOGNIZED, AND ALMOST UNIVERSALLY FATAL. ETIOLOGIES: VIRAL (HEV—sporadic, outbreaks, high mortality pregnancy), HBV (acute, reactivation), ATT-DILI (common, preventable), HERBAL MEDICINES (significant, underreported), WILSON'S (rare, diagnostic challenges), ACETAMINOPHEN (underrecognized—ASK). DIAGNOSTIC CHALLENGES: INR (available), ammonia (limited), acetaminophen level (not available), viral serology (HEV, HAV, HBV—available), autoimmune markers (ANA, SMA—available tertiary), ceruloplasmin (limited), liver biopsy (available tertiary). MANAGEMENT CHALLENGES: ICU capacity (limited), N-ACETYLCYSTEINE (available, essential medicine, USE IT for ALL ALF), CRRT (limited), intracranial pressure monitoring (not available), LIVER TRANSPLANT (NOT AVAILABLE). Thus, GOAL is: 1) EARLY RECOGNITION, 2) TRANSFER TO TERTIARY CENTRE (ICU), 3) AGGRESSIVE SUPPORTIVE CARE, 4) ETIOLOGY-SPECIFIC THERAPY (NAC, antivirals for HBV, steroids for AIH, delivery for AFLP, stop toxin), 5) CONSULTATION WITH TRANSPLANT CENTRE (South Africa?) for potential transfer (rare, expensive, not feasible for most). Prevention: HBV VACCINATION, safe blood products (HEV? not screened), safe food/water, limit acetaminophen (<4g/day), caution with ATT (monitor LFTs, patient education), AVOID HERBAL TOXINS. This is a LOW-VOLUME, HIGH-IMPACT, HIGH-MORTALITY topic. MASTER ALF: RECOGNIZE, RESUSCITATE, TRANSFER, NAC, IDENTIFY ETIOLOGY, TRANSPLANT EVALUATION.
-
Coming soon
Topic 197Coming soon
Choledochal Cysts: Congenital Biliary Dilatation
Choledochal cysts are rare congenital dilatations of the intrahepatic and/or extrahepatic biliary tree. For Zambian students, recognition is critical—they present in childhood or adulthood with non-specific symptoms, and carry a SIGNIFICANT RISK OF MALIGNANCY (cholangiocarcinoma) if not excised. Todani classification: Type I (80-90%): fusiform/saccular dilatation of common bile duct. Type II: diverticulum of extrahepatic duct. Type III (choledochocele): dilatation of intraduodenal bile duct. Type IV: multiple intrahepatic and extrahepatic cysts. Type V (Caroli's disease): intrahepatic cystic dilatation only. Clinical: classic triad (intermittent, <30%): abdominal pain, jaundice, palpable RUQ mass. Infant: obstructive jaundice, acholic stools. Child/adult: recurrent cholangitis, pancreatitis, or asymptomatic (imaging incidental). Diagnosis: ULTRASOUND (first-line): anechoic, subhepatic cyst separate from gallbladder, communication with biliary tree. MRCP: non-invasive gold standard—delineates cyst type, extent, biliopancreatic junction (long common channel). ERCP: therapeutic (sphincterotomy for choledochocele), diagnostic role replaced by MRCP. Management: COMPLETE CYST EXCISION + ROUX-EN-Y HEPATICOJEJUNOSTOMY (Type I, II, IV). Internal drainage (cystoduodenostomy) is OBSOLETE (high malignancy risk, up to 30%). Type III (choledochocele): endoscopic sphincterotomy. Type V (Caroli's): diffuse disease may require liver transplantation. Surveillance post-resection: annual imaging, CA19-9 (lifelong, residual malignancy risk). Prognosis: excellent after complete excision. Malignancy risk eliminated. Zambian context: RARE, but diagnostic challenge. Consider in child/adult with unexplained obstructive jaundice, recurrent cholangitis, or pancreatitis. Ultrasound + MRCP (tertiary). Surgical resection available (tertiary centres). High index suspicion.
-
Coming soon
Topic 198Coming soon
Gallbladder Cancer: The Silent Malignancy
Gallbladder cancer (GBC) is an aggressive, lethal malignancy with strong geographic and ethnic variation. For Zambian students, GBC is associated with CHRONIC INFLAMMATION: cholelithiasis (large stones >3cm, long-standing), PORCELAIN GALLBLADDER (wall calcification, 10-20% cancer risk), chronic typhoid carriage (S. typhi), and choledochal cysts (Type IV). Adenocarcinoma (90%). Clinical: SILENT, EARLY DISEASE IS ASYMPTOMATIC. LATE PRESENTATION: RUQ pain, weight loss, anorexia, jaundice (advanced, incurable). Incidental finding: post-cholecystectomy pathology (1% of cholecystectomies). Diagnosis: ULTRASOUND: mass replacing gallbladder, wall thickening (>1cm), loss of interface, gallstones. CECT (staging): hepatic invasion, lymphadenopathy, biliary obstruction, metastases. MRCP: biliary involvement. EUS-FNA: tissue diagnosis, not routinely required if surgical resection planned. Staging: T (tumour depth), N, M. Management: SURGICAL RESECTION is ONLY POTENTIAL CURE. Tis/T1a (mucosa): simple cholecystectomy SUFFICIENT (94% 5y survival). T1b (muscularis) or greater: RADICAL CHOLECYSTECTOMY (en bloc liver resection (IVb/V), portal lymphadenectomy, ± bile duct resection). ADVANCED (T3/T4, N+, M1): PALLIATIVE. Chemotherapy (gemcitabine/cisplatin) for metastatic disease. Biliary stenting for obstructive jaundice. Prognosis: EXTREMELY POOR. 5y survival: T1: 85-95%, T2: 60-70%, T3/T4: 20-30%, M1: <5%. PREVENTION: PROPHYLACTIC CHOLECYSTECTOMY for high-risk groups: porcelain gallbladder, stones >3cm, gallbladder polyp >10mm, chronic typhoid carriage, choledochal cysts. Zambian context: GBC is UNDERDIAGNOSED. Think GBC in elderly woman with long-standing gallstones, weight loss, RUQ mass. Ultrasound widely available. CT at tertiary centres. Surgical resection available. High index suspicion for incidental GBC after cholecystectomy—mandatory histopathology review.